A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma

References

• Siegel R, Ward E, Brawley O, . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212–236.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008.
   Google Scholar
• Fernandez V, Hartmann E, Ott G, . Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005;23: 6364–6369.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, . Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209–1213.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Hiddemann W; European MCL Network. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009:542–551.
   PubMedGoogle Scholar
• Herrmann A, Hoster E, Zwingers T, . Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511–518.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, . Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–1992.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, . High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, . Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Hosein PJ, Morgensztern D, . High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. Leuk Lymphoma 2010;51:406–414.
   PubMed Web of Science ®Google Scholar
• Tam CS, Bassett R, Ledesma C, . Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:4144–4152.
   PubMed Web of Science ®Google Scholar
• Leoni LM. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol 2011;48(Suppl. 1): S4–S11.
   Google Scholar
• Garnock-Jones KP. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Drugs 2010;70:1703–1718.
   PubMed Web of Science ®Google Scholar
• Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol 2010;66:413–423.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, . Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010;116:106–114.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, . Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204–210.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, . Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383–3389.
   PubMed Web of Science ®Google Scholar
• Herold M, Schulze A, Niederwieser D, . Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006;132:105–112.
   PubMed Web of Science ®Google Scholar
• Weide R, Hess G, Koppler H, . High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007;48:1299–1306.
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, . Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kelly JL, . The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807–2812.
   PubMed Web of Science ®Google Scholar
• Ohmachi K, Ando K, Ogura M, . Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010;101:2059–2064.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events version 4.0 (CTCAE). National Cancer Institute. 2009. Available from: http://www.ctep.cancer.gov/reporting/ctc_v30.html
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Collett D. Modeling survival data in medical research. London, England: Chapman & Hall; 1994.
   Google Scholar
• Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710–719.
   PubMed Web of Science ®Google Scholar
• Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001;12:725–729.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, . Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, . Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520–525.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Moskowitz C, Portlock C, . Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol 2009;145:34–39.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Lossos IS, Justice G, . Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145: 344–349.
   PubMed Web of Science ®Google Scholar
• Cohen BJ, Moskowitz C, Straus D, . Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001;42:1015–1022.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, . The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064–3071.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, . Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Ghobrial I, . Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347–5356.
   PubMed Web of Science ®Google Scholar
• Carson KR, Bennett CL. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma 2009;50:323–324.
   PubMed Web of Science ®Google Scholar